Abstract

Patients with chronic myeloproliferative neoplasms, including essential thrombocythemia (ET), polycythemia vera (PV), and chronic myeloid leukemia (CML), are at increased risk of new hematological malignancies, but their risk of non-hematological malignancies remains unknown. We thus assessed the risk of both types of malignancies after an ET, PV, or CML diagnosis. We linked two population-based nationwide registries, the Danish National Registry of Patients covering all Danish hospitals and the...